Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E24.90 EPS (ttm)3.95 Insider Own- Shs Outstand2.68B Perf Week0.81%
Market Cap263.25B Forward P/E18.07 EPS next Y5.44 Insider Trans- Shs Float415.24M Perf Month-4.68%
Income9.70B PEG3.48 EPS next Q1.34 Inst Own9.90% Short Float0.68% Perf Quarter-4.77%
Sales51.75B P/S5.09 EPS this Y16.20% Inst Trans0.11% Short Ratio1.59 Perf Half Y-1.72%
Book/sh32.60 P/B3.02 EPS next Y5.77% ROA15.00% Target Price113.50 Perf Year12.71%
Cash/sh2.17 P/C45.33 EPS next 5Y7.15% ROE26.30% 52W Range81.85 - 106.84 Perf YTD9.14%
Dividend2.67 P/FCF73.21 EPS past 5Y3.20% ROI10.50% 52W High-7.95% Beta0.68
Dividend %2.71% Quick Ratio0.60 Sales past 5Y3.50% Gross Margin66.60% 52W Low20.15% ATR1.88
Employees120000 Current Ratio0.80 Sales Q/Q-52.20% Oper. Margin21.40% RSI (14)43.80 Volatility2.77% 1.52%
OptionableYes Debt/Eq0.30 EPS Q/Q-63.50% Profit Margin37.80% Rel Volume0.83 Prev Close98.64
ShortableYes LT Debt/Eq0.17 EarningsJul 21 BMO Payout34.00% Avg Volume1.78M Price98.35
Recom1.80 SMA20-2.85% SMA50-3.24% SMA200-0.52% Volume1,481,943 Change-0.29%
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Aug-28-15 05:15PM  Lucky 7: These Stock Market Leaders Have Top Dividend Growth Rates at Investor's Business Daily
02:32PM  Swiss Miss: Switzerland Skirts Recession, But ETFs Struggle
09:36AM  Research and Markets: Investigation Report on China's Ranibizumab Market, 2012-2019 Business Wire
Aug-27-15 10:46AM  Things could get pricey if you wear contacts
08:00AM  Contact lens makers see their day in court
Aug-26-15 04:52PM  Getting a flu shot? There are new options
04:45PM  Novartis' (NVS) Promacta Label Further Expanded in U.S.
01:53PM  Glaxo in $1 Billion Ofatumumab Deal With Novartis at Investopedia
08:44AM  GlaxoSmithKline Lines Its Pockets Courtesy of Novartis Once Again at Motley Fool
Aug-24-15 03:04PM  FDA Grants Expanded Use of Promacta for Novartis
Aug-21-15 01:05PM  Novartis could pay more than $1B for GlaxoSmithKline MS drug
12:40PM  Novartis' Odomzo Gets European Approval for Skin Cancer
06:39AM  European Stocks Fall Further as Volatility Outweighs Strong Economic Data at TheStreet
03:30AM  European stocks plunge on China, Greece worries at CNBC
01:43AM  Novartis to Acquire Rights to Glaxo MS Drug for Up to $1 Billion at Bloomberg
Aug-20-15 06:30AM  How companies can enrich shareholdersand the planet at Fortune
Aug-19-15 12:34PM  Ford & General Motors: Ready to Go Full Bull? at
08:33AM  Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Aug-18-15 04:30PM  AVEO Up on Novartis Collaboration for Cachexia Candidate
10:33AM  Wait, There are Still Cheap Pharma Stocks? at
Aug-17-15 02:40PM  Aveo, the Cambridge biotech that refuses to die, sees stock jump after $326M deal at
10:44AM  Tesla price upgrade; J.C. Penney boost; AVEO's big deal; QVC shops for zulily
09:45AM  Is AVEO the Next Aquinox for Traders? at 24/7 Wall St.
09:35AM  Novartis AG Earnings Q2*, 2015
Aug-14-15 03:45PM  Bristol-Myers Leukemia Drug Sprycel's U.S. Label Updated
Aug-13-15 09:35AM  Theravance, Inc. Earnings Q2*, 2015
Aug-12-15 05:03PM  Pfizer Stock Is Like An Extended Release Drug at Investopedia
10:12AM  Dr. Reddys Laboratories Ltd. Earnings Q2*, 2015
Aug-10-15 01:31AM  Australia's CSL warns of biotech bubble at Financial Times
Aug-07-15 12:00AM  Glaxos Best Headache Remedy May Be Buying Stakes in Ventures at Bloomberg
12:00AM  Glaxo's Best Headache' Remedy May Be Buying Stakes in Ventures
Aug-06-15 06:00AM  Research and Markets: Investigation Report on China's Octreotide Market 2010-2019 Business Wire
Aug-05-15 03:15PM  Yelp Beefs Up Its Health Information Service at Investor's Business Daily
11:50AM  Momenta's (MNTA) Q2 Loss Narrows Y/Y, Glatopa in Focus - Analyst Blog
09:12AM  4 Pharmaceutical Stocks to Buy in Wake of Shire-Baxalta Bid at TheStreet
01:50AM  Are we seeing a new dawn of innovation in pharma? at CNBC
Aug-04-15 04:40PM  Momenta Has Momentum at Motley Fool
03:44PM  Will Biogen Win From Novartis MS Drug Safety Label Change?
07:56AM  Merck & Co., Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-03-15 04:59PM  5 Biotechs With Catalysts Coming This Week
03:05PM  Teva Can Benefit by Acquiring Allergan Generics
03:01PM  Teva Announces Its Acquisition of Allergan Generics
12:53PM  Valeant Pharmaceuticals International, Inc. Earnings Q2*, 2015
11:11AM  ETF Analysis: Vanguard International Stock at Investopedia
Aug-02-15 07:47PM  CSL completes Novartis flu vaccine deal AAP
Jul-31-15 09:03AM  Teva's Q2 Earnings & Revenues Beat Expectations, View Up - Analyst Blog
Jul-30-15 06:51PM  Amgen hikes 2015 forecast after 2Q increase in profit, sales
11:32AM  GlaxoSmithKline (GSK) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
10:30AM  Glaxo Up on Q2 Earnings Beat, Revenues Rise, View Same - Analyst Blog
09:06AM  Novartiss Shares Fall after 2Q15 Earnings
08:56AM  Valeant Pharmaceuticals International, Inc. Earnings Analysis: By the Numbers
Jul-29-15 01:30PM  GSK Boosted by New Vaccines at The Wall Street Journal
11:28AM  HIV/Aids treatments stand out as GSK promises 40-drug pipeline at Financial Times
11:06AM  Why Sandoz Revenues Were Important for Novartis in 2Q15
10:00AM  GSK earnings relief
09:06AM  Why Alcons Performance Was Weak in 2Q15
09:04AM  Eli Lilly & Co. Earnings Analysis: By the Numbers
09:04AM  GSK flags up pipeline as HIV drugs help it beat profit forecasts
08:56AM  Glaxo Earnings Beat Estimates on AIDS Drugs, Cost Reductions at Bloomberg
08:30AM  Drugmaker GSK sees earnings growth returning in 2016
08:16AM  GSK sees drop in earnings after asset swap with Novartis
07:37AM  GlaxoSmithKline second-quarter beats despite Advair hit, lower margins
07:10AM  GlaxoSmithKline Q2 beats despite Advair hit, lower margins
Jul-28-15 02:54PM  Why Pharmaceutical Eli Lilly & Co. Warrants Attention from Investors Right Now - Stocks in the News
11:46AM  Why Novartiss Revenues Declined Marginally
11:45AM  Novartiss Adjusted Earnings per Share Declined 7% in 2Q15
Jul-27-15 06:02AM  New heart drugs come in more expensive than expected Reuters
Jul-24-15 05:17PM  FDA OK's Odomzo from Novartis for common skin cancer type
02:49PM  FDA OK's Odomza from Novartis for common skin cancer type
11:12AM  AbbVie: Beware the Biosimilars? at
Jul-22-15 01:41PM  Court of Appeals Biosimilars Decision Does Not Assure Zarxio Launch in September
12:35PM  New IndexIQ ETFs Bring the Neutral to Currency Hedged ETFs
10:43AM  Novartis (NVS) Beats on Earnings in Q2, 2015 View Retained - Analyst Blog
10:10AM  Company News for July 22, 2015 - Corporate Summary
12:13AM  Novartis Can Sell Copycat of Amgens Neupogen in September, Court Rules at The Wall Street Journal
Jul-21-15 08:14PM  Appeals court says rival can sell copy of Amgen drug Neupogen at Los Angeles Times
06:40PM  Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
06:38PM  Will Currency and Generics Hit Eli Lilly's Q2 Earnings? - Analyst Blog
03:54PM  Court ruling clears way for Novartis' low-cost biotech drug
02:54PM  Novartis Can Sell Copycat of Amgen's Neupogen in September at The Wall Street Journal
01:37PM  Novartis (NVS) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
01:15PM  Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles at Investor's Business Daily
10:24AM  Novartis Blurs Vision of Its Potential at The Wall Street Journal
08:48AM  3 High-Dividend Pharmaceutical Stocks to Buy at TheStreet
08:19AM  Novartis CEO Says U.S. Insurance M&A to Crimp Drug Prices
08:04AM  Early movers: TRV, UTX, VZ, RF, DEPO, NKE & more at CNBC
07:51AM  European shares fall, pulled down by drugmakers
07:44AM  Novartis earnings fall, CEO focuses on heart drug at CNBC
07:36AM  Novartis chief looks to blockbuster drugs to counter profits drop at Financial Times
06:13AM  Novartis' now offers generic MS drug: CEO
05:45AM  Novartis Profit Misses Estimates Amid Weak Lens Unit Sales
05:28AM  Weak eyecare sales trip up Novartis drug growth story
04:51AM  Novartis bullish on Afinitor cancer drug despite new competition
04:32AM  Financial Institutions in Greece Remain Closed
04:30AM  Drugmakers push European shares further away from highs
03:50AM  Novartis Profit Misses Estimates Amid Faltering Lens Unit Sales at Bloomberg
03:17AM  Novartis (NVS) Beats on Earnings & Revenues in Q2 - Tale of the Tape
03:06AM  Strong dollar hits Novartis; reports profit miss at CNBC
02:06AM  Novartis Profit Drops as U.S. Dollar Strength Erodes Sales
01:45AM  Looking at bolt-on acquisitions: Novartis CEO
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company's Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerSep 22Buy15.00325,0004,875,0004,644,328Sep 24 05:42 PM